Bio Screening Industry News

FREE Weighing & Pipetting Skills and Solutions Seminar on Thursday, December 3, 2009 at the Doubletree Hotel & Executive Meeting Center in Somerset, NJ.

In these challenging times where training budgets are stretched and laboratories are searching for new efficiencies to improve productivity, METTLER TOLEDO can help. This half-day Insight! Education seminar will focus on the METTLER TOLEDO Good Weighing Practice™ (GWP®) program and Pipetting 360° from RAININ, and will include an introduction to associated solutions for the laboratory. The seminar is valued at $495.00 per person, but is completely free of charge with your advance registration - however, space is limited, so register today!

Learn from Acknowledged Industry Authorities:

Proper weighing and pipetting skills and operations are fundamental laboratory functions critical to achieving accurate results in your analytical processes. Yet, there is often confusion on many aspects with regards to balance and pipette use and operation.

Instructor - Henry Oppermann, former Division Chief for Weights and Measures, National Instituted of Standards [NIST].

Learn the Good Weighing Practice (GWP®) approach to selection, use, calibration, and ongoing management of balances for your laboratory, department, or even entire organization from an acknowledged industry authority. During his career, Henry Oppermann has been instrumental in developing many of the guidelines and practices designed to improve weighing processes. Join him and experts from METTLER TOLEDO for this insightful session.

Together with knowledgeable experts on the RAININ 360° approach to pipette use and management, you’ll learn valuable risk-based approaches to working with two of the most common - yet critical instruments in the lab, that will enhance your skills, career and results in any industry setting!

Also, we’re pleased to introduce Quantos - a revolutionary innovation for routine and precise dosing of powder compounds in the lab. Quantos is the winner of the 2009 Lab Automation Association and R&D 100 Awards! Learn more about how Quantos can improve speed, safety, and savings in your lab. See Quantos and a variety of other METTLER TOLEDO solutions live following the seminar during our product exposition.

If you think a colleague would be interested in attending this informative seminar, then forward to a colleague.

Date:    Thursday, December 3, 2009
Time:    8:30 am - 12:15 pm (Continental Breakfast at 8:00am / Lunch following seminar.)
Cost:    FREE with Advance Registration. Hurry - Space is limited! Free parking.
Location:    Doubletree Hotel & Executive Meeting Center 200 Atrium Drive, Somerset, New Jersey 08873

Schedule

Time:
8:00am – 8:30am Arrival & Check-in with Complimentary Continental Breakfast
8:30am – 12:15pm Seminar and speakers
12:15pm – 1:30pm Complimentary lunch concurrent with product exposition
Free parking.

Cost:
FREE with Registration (A $495 Insight! Education value)

Agenda:

8:00 am – 8:30 am: Check-in and Complimentary Continental Breakfast

8:30 am to 10:15 am – Good Weighing Practice™ GWP® Presented by Henry Oppermann, Former Division Chief for Weights and Measures at the National Institutes of Standards and Technology (NIST).

Minimize weighing risks with a minimum of effort. Good Weighing Practice allows you to improve control of your whole measuring process from balance Evaluation, Selection, Installation, Calibration and Routine Operation. With Good Weighing Practice you weigh without risks, comply with regulations easily, and achieve consistent good quality of your product and analytical processes appropriate for your industry or application.  Click here to learn more about Good Weighing Practice.

10:15 am to 10:30 am – Break

10:30 am to 10:55 am - Minimizing Weighing Measurement Uncertainty
METTLER TOLEDO knows it is essential for you to produce accurate results, achieve compliance, and improve traceability in the lab. See how to address all requirements regarding measurement uncertainty as outlined in ISO 17025 and ISO 9000/9001. Ensure strict compliance with your Quality Management SOP’s. Verify all calibrations and automatically perform routine weight checks on schedule while efficiently capturing your weighing data transparently while meeting all regulatory requirements.

10:55 am to 11:20 am – A New Solution in Automated Powder Dosing
New QUANTOS™ from METTLER TOLEDO solves many of the challenges of repetitive weighing of powder materials, such as reference standards for use with chromatography and other analytical lab applications, capsule filling or inhaler work, bottling, and more. Precise dosing of small amounts of powder in the Bio/Pharmaceutical or the chemical laboratory is a difficult, time consuming, and potentially hazardous task. Often the scientist is in contact with highly potent compounds or has a limited amount of precious material, and dosing may be hindered by electrostatic or hygroscopic effects. QUANTOS solves these challenges and more. Click here to learn more about QUANTOS™.

11:20 am to 12:15 pm – Good Practices in Pipette Use and Management - Pipetting 360°
Pipette liquid handling involves a variety of principles and practical considerations. This informative presentation from RAININ will cover handling principles with practical considerations, address how to best maximize accuracy & performance technique in your pipette work, tip selection and application, calibration approaches and solutions, and steps you can take to improve your results and productivity. Click here to learn more about RAININ Pipettes.

12:15 pm – 1:30 pm – Complimentary Lunch and Product Exposition
A Free Product Exposition will run concurrent with and following a noon luncheon where you can see a variety of these and other METTLER TOLEDO and RAININ Solutions displayed and demonstrated, while having your questions answered.

Exposition Products and Technologies will include:

* Analytical, Precision, and MicroBalances from METTLER TOLEDO
* QUANTOS® Perfect Dosing Solution
* RAININ Pipette Solutions including the New Rainin Liquidator 96 Benchtop Pipetting System
* Pipette Calibration Workstations
* Potentiometric and Karl Fischer Titrators from METTLER TOLEDO
* Density & Refractometry Systems
* pH measurement solutions
* Thermal Analysis including DSC, TGA, TMA, and DMA technologies and melting point solutions
* Moisture Balances
* LabX Software for Balance and Instrument control and data capture.
* And more…

1:30 pm – Conclude

Doubletree Hotel & Executive Meeting Center
200 Atrium Drive
Somerset, New Jersey 08873

http://mt.com/us/en/home/events/fairs/somerset_semin.html

Beltsville, MD; and Hyderbad, AP, India, October 21, 2009 – BioServe, a leading provider of clinical bio-samples and research services, today announced that it has been selected by the Government of the State of Andhra Pradesh in India and The Institute of Preventive Medicine (IPM) Hyderabad as one of two private diagnostic centers to test samples of Influenza A - H1N1 (Swine Flu) in afflicted patients. BioServe’s ISO 9001:2008 and ISO 17025:2005 (NABL) certified genomic laboratory in Hyderabad, India is one of the most advanced full-service reference laboratories in the country.

In addition, to help prepare the Indian health system for a robust response to pandemic outbreaks of swine flu, BioServe is also developing a powerful one-step PCR diagnostic test for effective identification of swine flu, at a price point that makes it possible to carry out mass screenings of large populations in India. The test will be certified in accordance with the prevailing guidelines for diagnosis of virus strains, and is scheduled for a market launch upon due validation and verification.

According to the Indian Government’s most recent data, there have been 12,880 confirmed cases of swine flu and 415 deaths from the virus. The country’s Ministry of Health views the addition of BioServe’s new diagnostic center as critical to expediting the testing of swine flu samples, which will enable the authorities to diagnose more cases and start treatment immediately, thus mitigating the risks of spreading the disease further throughout the population.

Rama Modali, President, BioServe, said, “We are proud to be a key part in India’s fight against the pandemic outbreaks of swine flu. BioServe’s clinical testing labs, as well as our indigenous swine flu diagnostic test currently in development, will help provide the rapid and accurate diagnoses that are critical to disease containment and treatment in  India and countries around the world.”

About BioServe

BioServe provides pharmaceutical, biotechnology, clinical and academic research markets with comprehensive ‘biomaterial to validated data’ genomic research services that generate pre-clinical data needed for breakthroughs in drug discovery and molecular diagnostics.  BioServe’s services feature over 600,000 high quality, well-annotated and clinically relevant biological specimens from its Global Repository® and a suite of complimentary CLIA-certified genomic research services. Used together or separately BioServe’s genomic services enable biomedical researchers to efficiently conduct genomic and proteomic research,  validate drug and diagnostic targets  and correlate clinical data with molecular data for the development of improved drugs and diagnostics.  BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

Cologne, Germany, October 01, 2009 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes and the contract manufacturer InVivo BioTech Services GmbH announced today the signing of a strategic license agreement. This license enables InVivo to offer its customers the production of their diagnostic ad preclinical grade material very fast and in highest quality, including authentic human glycosylation patterns, using the novel and proprietary CAP-T™ transient expression system.

CAP-T™ Technology is based on CAP® cells, the stable cell line from CEVEC. The non-tumor origin cells have high expression rates of human proteins and grow in serum-free suspension culture and post-translational modifications are human-like. Process times are reduced by means of large-scale transient transfection.

“After launching our new transient cell in the US market we are delighted to have now our first customers in Europe not only using our stable expression system but also working with our new transiently expressing human cell line. With expression rates outperforming any other human system on the market, e.g. HEK 293 freestyle and others, while offering highest quality human like proteins, we offer our customers a unique state of the art cell line,”  Wolfgang Kintzel, CCO of CEVEC Pharmaceuticals GmbH states.

Rainer Lichtenberger, CEO of CEVEC, adds. “Because posttranslational modifications play a significant role for the bioactivity of recombinant proteins it is of crucial importance to produce proteins with human-like glycosylation and sialylation. With our proprietary human cell lines, CAP for permanent producer cells for proteins and the novel CAP-T system, only CEVEC is able to offer a unique range of versatile human cell expression systems to our customers, from early discovery to protein manufacture. This license agreement contributes significantly to CEVECs goal becoming the leading cell line supplier for protein production with human cell expression systems.”

Link to the news release
About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne, Germany. Based on their experience and theirlongstanding collaborative work they had experienced a lack of innovative expression systems formore efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules with human glycosylation patterns.

About InVivo BioTech Services GmbH - www.invivo.de
InVivo is a contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins. Based in Hennigsdorf, Germany, just outside Berlin, InVivo is an ISO 9001 certified company with over ten years experience in mammalian cell culture and protein production. More than 1100 different hybridomas have been cultivated in InVivo’s proprietary serum-free media ISF1 for high productivity and cost benefits in cultivation and purification. Furthermore InVivo offers the complete range of modern protein expression techniques. Starting from synthetic or amplified cDNA your protein can be stable expressed in bacteria, insect and mammalian cell lines or alternatively transient expressed.

COPENHAGEN, Denmark, July 28 /PRNewswire/ — Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline.

The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads. These technologies were developed by Nuevolution and Praecis Pharmaceuticals, a wholly owned subsidiary of GlaxoSmithKline.

Under the terms of the cross-licensing agreement, GlaxoSmithKline will obtain a non-exclusive license under technology patents of Nuevolution, and Nuevolution will obtain a one time license fee and a non-exclusive license under technology patents of GlaxoSmithKline.

Further details of the agreement are not disclosed.

“By entering into this agreement, both companies are offered an optimal basis for continued development and application of the technologies” said Allen Oliff, SVP Molecular Discovery Research of GSK and Alex Gouliaev, CEO of Nuevolution A/S continued “our innovative technologies allow small molecule hit and lead discovery at an unprecedented scale. This agreement secures both companies the rights to operate these powerful technologies to their fullest extent”.

About Nuevolution

Nuevolution is a leading lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based lead discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing lead discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Invest and Novo A/S. For more information about Nuevolution A/S, please visit the company’s website http://www.nuevolution.com

Menlo Park, Calif.—July 22 , 2009—SRI International, an independent nonprofit research and development organization, announced today that SRI’s Center for Cancer Research was selected by the National Cancer Institute (NCI) for a leading role in the newly-formed “Chemical Biology Consortium” (CBC), a collaborative drug discovery partnership focused on advancing new cancer therapeutics active against novel molecular and genetic cancer targets. Based on its track record of cancer drug discovery and development, SRI was chosen to lead three of the CBC’s research and development centers: Comprehensive Chemical Biology Screening, Chemical Diversity, and Specialized Applications.

SRI has decades of experience in successfully identifying, developing and advancing novel compounds into clinical evaluation. SRI’s Center for Cancer Research, comprised of biologists and medicinal chemists with expertise in fundamental and applied cancer research, focuses on the study of tumor microenvironment, tumor metabolism, and aberrant signaling pathways that cause cancer. Through collaborative partnerships, SRI’s Center for Cancer Research has been successful in generating an extensive drug pipeline translating discoveries into beneficial treatments. SRI’s drug discovery process, guided by a combination of biological screens and computational methods, will be a key component of the NCI Chemical Biology Consortium program.

“SRI is proud to be selected to join this innovative NCI program and to continue our long-standing support of NCI’s mission to discover, develop, and bring new drugs to cancer patients,” said Lidia Sambucetti, Ph.D., senior director of SRI’s Center for Cancer Research. “Our multidisciplinary research team will bring proven expertise in fundamental and applied cancer research, backed by SRI’s fully-integrated preclinical capabilities.”

The goal of the Chemical Biology Consortium is to discover and develop new cancer therapeutics, particularly those that are beyond the scope of standard biopharmaceutical practice. The CBC will focus on therapeutic opportunities in high-risk, under-represented areas to advance the discovery of compounds active against novel molecular and genetic cancer targets.

Sambucetti will serve as the overall principal investigator of SRI’s CBC program and the Comprehensive Chemical Biology Screening Center. She will collaborate with Mary Tanga, Ph.D., an SRI senior director of medicinal chemistry, who will lead the Chemical Diversity Center, and Keith Laderoute, Ph.D., an SRI distinguished scientist, who will lead the Specialized Applications Center.

As the principal investigator of the Comprehensive Chemical Biology Screening Center, Sambucetti was invited to join the CBC Steering Committee, an NCI advisory panel that will work to ensure that CBC Centers are efficiently bridging the gap between basic scientific findings and NCI-supported clinical research.

To optimize high-quality leads and accelerate the drug discovery process, SRI will be working with BioComputing Group, Inc., a developer of computational screening, hit-to-lead, and lead optimization tools with particular emphasis on structure-guided drug discovery. These tools employ novel molecular descriptors that are derived from active compounds within the target family and from the structure of the target protein that can be applied to the evaluation of compounds from a library as well as compounds not yet synthesized. BioComputing Group, Inc. (www.BioPredict.com) has a significant track record of success in applying its tools in a hypothesis-driven paradigm to accelerate drug discovery efforts of its collaborators and clients, having placed multiple compounds into clinic with significantly reduced numbers of compounds screened and synthesized and with significantly shortened time frames.

This project has been funded in whole or in part with Federal Funds from the National Cancer Institute, National Institutes of Health, under Contract No. N01-C0-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.

About SRI’s Biosciences Division

SRI International’s Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all of the resources necessary to take R&D programs from “idea to IND”™—from initial discovery to investigational new drug applications to start human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience research. SRI’s internal drug pipeline has yielded several marketed drugs, several additional drugs currently in clinical trials, and more than a dozen programs in preclinical development or early discovery. In its CRO business, SRI has helped advance more than 100 drugs into clinical trials, several of which have reached the market. SRI is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International is one of the world’s leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2008, SRI’s consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $490 million.

Source: www.sri.com

VANCOUVER, BC — (Marketwire) — 07/16/09 — Sirona Biochem Corp. (TSX-V: SBM) announced today it is now ready to begin testing its novel new compounds to fight diabetes and obesity.

The completion of the company’s key SGLT biological assessment test and testing will be done under contract with Richmond, BC based SignalChem.

Sirona Biochem owns the worldwide rights to a library of potential new sodium glucose transporter (SGLT) inhibitors developed to treat diabetes and obesity. SGLT Inhibitors are a novel new drug class currently under development that block the reuptake of excess sugars from urine in the kidney which can then reduce high blood sugar to normal levels. Excess sugar in the blood is a primary medical challenge associated with treating diabetes and obesity.

Sirona has a research and development agreement with TFChem (Rouen, France), where a significant number of SGLT drug analogs are being prepared for first stage evaluation. Preliminary primary stage testing conducted earlier this year provided positive indications to support Sirona Biochem’s project and provided key insights to optimize the new test that is now ready for use to evaluate the next library set of molecules.

Mark Senner, President, explained, “SGLT inhibitors are a new and exciting class of compounds that have great promise to treat both diabetes and obesity which are now at epidemic levels worldwide. This new drug class is one considered to have extraordinary market potential in the fight against diabetes and obesity.

“Development of this new drug class however is challenging due to the fragile nature of these ’sugar’ based molecules that render them unstable and difficult to develop for clinical use. Given this challenge, it is believed that the use of the patented GlycoMim® technology, licensed from TFChem to develop SGLT Inhibitors, will increase drug stability and, therefore, improve their overall clinical effectiveness. Potential licensing and development partners have expressed interest in our concept of improving molecules in this new drug class. We intend to develop ‘best in class’ SGLT Inhibitors through use of this technology.

“The key and critical first test has been developed and optimized for use by SignalChem under contract from Sirona Biochem. Through use of this proprietary test, the company will be able to determine which molecules have the desired potency and selectivity compared to a reference standard. Screening of the current library of compounds will generate key data for ongoing drug development and provide first stage proof of concept necessary to secure future partnering opportunities. Sirona’s scientific team aims to identify lead compounds by the end of 2009,” continued Senner.

“The results from our new optimized test will be critical to direct our ongoing development of novel new SGLT inhibitors. The development and optimization of this sophisticated test, completed by SignalChem, is a significant and key milestone achievement for us. We are very pleased with the progress that we are making on our SGLT drug development program,” commented Senner.

Upon selection of compounds with the desired potency and selectivity for the SGLT 2 carrier protein, further preclinical screening for cytotoxicity, ADME properties, pharmacokinetics and in vivo efficacy will need to be carried out to select compounds for future clinical development. The primary objective of this critical first stage development plan with SignalChem was to develop, qualify and optimize the key test required for the initial development of SGLT inhibitors.

Investors are invited to visit the Sirona Biochem website at: http://www.sironabiochem.com where we feature the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to info@sironabiochem.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466.

About the Company:

Sirona Biochem Corp. (TSX-V: SBM) is a emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II Diabetes and Obesity. Sirona has entered into a license agreement with TFChem S.A.R.L., a Drug Discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as S.G.L.T. inhibitors. S.G.L.T. inhibitors are a new and exciting class of compounds that have great promise and potential to treat both diabetes and obesity.

About SignalChem:

SignalChem, based in Richmond, B.C., Canada is a biotechnology company focused on the research, development and production of innovative cell signaling products to advance basic research and drug discovery efforts, with specific emphasis on the production of highly purified biologically active human recombinant proteins. SignalChem is emerging as a leader and a key contender in the life science recombinant protein market place. SignalChem offers a comprehensive discovery service which includes: gene cloning & expression of therapeutic ‘targets,’ custom assay & antibody development and compound profiling for drug ‘potency’ & ’selectivity.’

Mark Senner
President and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem
950-789 West Pender Street
Vancouver, B.C., V6C 1H2
Direct: 604-641-4466
Fax: 604-608-5471
info@sironabiochem.com

Source: www.sys-con.com

SOURCE Cognition Therapeutics Inc.

Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalised’ medicine.

Horizon Discovery is a translational genomics company founded in June 2007 and is headquartered at the Babraham Research Campus, Cambridge, UK and with additional research laboratories in Torino, Italy. Horizon’s goal is to convert new information on the genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery’s offering of X-MAN cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds – a missing link in the rational and efficient development of novel targeted anti-cancer agents.

Source: Cambridge Network

The Vaccines Development Conference brings together scientists and industry experts from pharma, biotech, academia and government to share what’s working and not working for them, and to address your key vaccine development challenges and questions.

The Vaccines Development Conference

With increasing applications in research to provide sensitive quantitative measurements of gene expression, including SNP genotyping, mutation detection and quantification, and gene dosage studies, quantitative polymerase chain reaction technology (qPCR) could soon be the standard for determining the genetic changes in response to a pharmacological agent.

Topic Overview

* Biomarkers clinic
* Increasing through-put
* Solid Phase Gene Expression
* Data Management
* Whole Genome Expression Profiling

Why should you attend this event?

With equipment improving all the time to offer high assay throughput and shorter assay times there has never been a better time to review existing technology, and how it can be applied to research & development in your organisation.

Unique in the market place, the inaugural SMi Quantitative Polymerase Chain Reaction (qPCR) & Transcriptional Profiling conference brings together industry leaders to discuss opportunities, advances in technology and time saving strategies.  The agenda is case study led, allowing delegates to benchmark their own research against that of their peers.

The qPCR and Transcriptional Profiling event is exclusively designed for the senior level practitioners from the world’s leading pharmaceutical and biotechnology companies.

This exclusive event consists of world-class keynote addresses, panel discussions and case-study sessions on all aspects of qPCR and Transcriptional Profiling, Biostatistics, increasing through-put, microarrays, microRNA expression and an exclusive Biomarkers Clinic!

Don’t miss out on this unique opportunity to increase your throughput, decrease costs and time and make your qPCR really work for you.  Can your company afford not to attend?

qPCR - Quantitive Polymerase Chain Reaction & Transcriptional Profiling